Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylphenidate improves HIV-1-associated cognitive slowing.

C H Hinkin1, S A Castellon, D J Hardy

  • 1Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles 90024, USA. chinkin@ucla.edu

The Journal of Neuropsychiatry and Clinical Neurosciences
|July 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palmar squamous cell carcinoma.

Annales de dermatologie et de venereologie·2025
Same author

Dental Visits for Autistic Children: A Qualitative Focus Group Study of Parental Perceptions.

JDR clinical and translational research·2021
Same author

Multilaboratory Comparison of Omadacycline MIC Test Strip to Broth Microdilution MIC against Gram-Negative, Gram-Positive, and Fastidious Bacteria.

Journal of clinical microbiology·2021
Same author

Scalable Molecular Dynamics with NAMD on the Summit System.

IBM journal of research and development·2020
Same author

Multilab evaluation of delafloxacin MIC Test Strip against Gram-negative and Gram-positive organisms.

Diagnostic microbiology and infectious disease·2019
Same author

Caries Detection with Near-Infrared Transillumination Using Deep Learning.

Journal of dental research·2019

Methylphenidate (MPH) may improve cognitive slowing in individuals with HIV-1. The drug showed benefits for those with more significant cognitive or depressive symptoms, but not for those without these deficits.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Infectious Diseases

Background:

  • HIV-1 infection can lead to cognitive slowing and depressive symptoms.
  • Information processing deficits are a significant concern for individuals living with HIV-1.

Purpose of the Study:

  • To evaluate the effectiveness of methylphenidate (MPH) in treating cognitive slowing associated with HIV-1 infection.
  • To determine if MPH impacts depressive symptomatology in this population.

Main Methods:

  • A single-blind, placebo-controlled, crossover study involving 16 HIV-1 seropositive individuals.
  • Participants received 30 mg/day of methylphenidate (MPH) or placebo.
  • Computerized tests measured choice and dual-task reaction time, alongside assessments of depressive symptoms.

Related Experiment Videos

Main Results:

  • Participants with greater baseline cognitive slowing or depressive symptoms showed improved reaction times with MPH.
  • Individuals without cognitive slowing at baseline did not exhibit significant improvement with MPH compared to placebo.
  • Methylphenidate (MPH) did not demonstrate a superior effect on depressive symptoms compared to placebo.

Conclusions:

  • Pharmacologic intervention with methylphenidate (MPH), a dopamine agonist, shows potential for treating information processing slowing in HIV-1 infection.
  • Clinical use of MPH may be best reserved for HIV-1 patients presenting with more pronounced cognitive and affective deficits.